A Phase 4 Study to Evaluate Adrenal Function in Hypogonadal Men Treated With JATENZO® for 12 Months

PHASE4Active, not recruitingINTERVENTIONAL
Enrollment

110

Participants

Timeline

Start Date

May 10, 2024

Primary Completion Date

November 30, 2025

Study Completion Date

March 31, 2026

Conditions
Hypogonadism
Interventions
DRUG

Jatenzo

237 mg JATENZO twice daily

Trial Locations (27)

11530

AccuMed Research Associates, Garden City

14609

Rochester Clinical Research, LLC, Rochester

21045

Centennial Medical Group, Columbia

23507

Alliance for Multispecialty Research, Norfolk

27609

Raleigh Medical Group, Raleigh

27701

Velocity Clinical Research, Inc., Durham

28401

Wilmington Health, PLLC, Wilmington

28602

Catawba Valley Medical Group, Inc., Hickory

28625

Piedmont Healthcare, PA, Statesville

31406

Velocity Clinical Research, Savannah

32720

Hillcrest Medical Research, LLC, DeLand

33060

Clinical Research Center of Florida, Pompano Beach

33135

Global Health Clinical Trial Crop, Miami

33176

Reserka LLC, Miami

34470

Renstar Medical Research, Ocala

53144

Clinical Investigation Specialists, Inc., Kenosha

68134

Velocity Clinical Research, Omaha

75041

VAST Clinical Research LLC, Garland

75115

Epic Medical Research LLC, DeSoto

75149

SMS Clinical Research LLC, Mesquite

78759

Velocity Clinical Research, Austin

84015

Alpine Research Organization, Inc., Clinton

84124

Highland Clinical Research, Salt Lake City

85281

Alliance for Multispecialty Research, Tempe

90805

Long Beach Research Institute, LLC, Long Beach

91356

Integrated Clinical Research, Tarzana

95648

Clinical Trials Research, Lincoln

Sponsors

Collaborators (1)

All Listed Sponsors
collaborator

ICON plc

INDUSTRY

lead

Tolmar Inc.

INDUSTRY

NCT06385509 - A Phase 4 Study to Evaluate Adrenal Function in Hypogonadal Men Treated With JATENZO® for 12 Months | Biotech Hunter | Biotech Hunter